LINCOLN Q1 FY27 results at a glance
LINCOLN PHARMA LTD Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹177 cr |
|---|
| Revenue YoY | +15.1% |
|---|
| Operating profit | ₹23.55 cr |
|---|
| Operating margin | 13.3% |
|---|
| Net profit | ₹36.23 cr |
|---|
| Net profit YoY | +30.9% |
|---|
| Net profit QoQ | +211.4% |
|---|
| Net margin | 20.4% |
|---|
| Basic EPS | ₹18.09 |
|---|
| TTM revenue | ₹694 cr |
|---|
| TTM net profit | ₹96.45 cr |
|---|
| TTM net margin | 13.9% |
|---|
LINCOLN Q1 FY27 results: what the numbers say
LINCOLN PHARMA LTD (LINCOLN) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹177 cr and a net profit of ₹36.23 cr, translating into earnings per share of ₹18.09.
Compared with the same quarter a year earlier, revenue grew by +15.1% and net profit grew strongly by +30.9%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹23.55 cr, an operating margin of 13.3% versus 13.2% a year ago — a gain of 0.1 percentage points.
LINCOLN quarter-wise results table
Net profit
₹36.23 cr
+30.9% YoY
Operating profit
₹23.55 cr
+15.8% YoY
LINCOLN PHARMA LTD (LINCOLN) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹177 cr | ₹23.55 cr | ₹36.23 cr | 13.3% | 20.4% | ₹18.09 | +30.9% | +211.4% |
| Q4 FY262026-03-31 | ₹187 cr | ₹21.17 cr | ₹11.63 cr | 11.3% | 6.2% | ₹5.81 | — | -59.3% |
| Q3 FY262025-12-31 | ₹166 cr | ₹19.88 cr | ₹28.6 cr | 11.9% | 17.2% | ₹14.28 | — | +43.1% |
| Q2 FY262025-09-30 | ₹163 cr | ₹21.81 cr | ₹19.98 cr | 13.4% | 12.2% | ₹9.98 | — | -27.8% |
| Q1 FY262025-06-30 | ₹154 cr | ₹20.33 cr | ₹27.68 cr | 13.2% | 18.0% | ₹13.82 | — | — |
| TTM (last 4 quarters) | ₹694 cr | ₹86.4 cr | ₹96.45 cr | 12.4% | 13.9% | ₹48.16 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
LINCOLN quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
LINCOLN PHARMA LTD quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹177 cr | ₹187 cr | ₹166 cr | ₹163 cr | ₹154 cr |
|---|
| Total expenses | ₹154 cr | ₹166 cr | ₹146 cr | ₹142 cr | ₹134 cr |
|---|
| Gross profit | ₹92.14 cr | ₹98.21 cr | ₹90.36 cr | ₹86.62 cr | ₹84.68 cr |
|---|
| Operating profit (EBIT) | ₹23.55 cr | ₹21.17 cr | ₹19.88 cr | ₹21.81 cr | ₹20.33 cr |
|---|
| Operating margin | 13.3% | 11.3% | 11.9% | 13.4% | 13.2% |
|---|
| Interest cost | ₹0.26 cr | ₹0.27 cr | ₹0.3 cr | ₹0.23 cr | ₹0.21 cr |
|---|
| Profit before tax | ₹47.55 cr | ₹16.7 cr | ₹34.72 cr | ₹28.81 cr | ₹35.39 cr |
|---|
| Tax expense | ₹11.32 cr | ₹5.07 cr | ₹6.12 cr | ₹8.83 cr | ₹7.71 cr |
|---|
| Effective tax rate | 23.8% | 30.3% | 17.6% | 30.6% | 21.8% |
|---|
| Net profit (PAT) | ₹36.23 cr | ₹11.63 cr | ₹28.6 cr | ₹19.98 cr | ₹27.68 cr |
|---|
| Net profit margin | 20.4% | 6.2% | 17.2% | 12.2% | 18.0% |
|---|
| Basic EPS | ₹18.09 | ₹5.81 | ₹14.28 | ₹9.98 | ₹13.82 |
|---|
| Diluted EPS | ₹18.09 | ₹5.81 | ₹14.28 | ₹9.98 | ₹13.82 |
|---|
LINCOLN results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +15.1% | — | — | — | — |
|---|
| Revenue QoQ | -5.3% | +12.6% | +1.8% | +6.0% | — |
|---|
| Operating profit YoY | +15.8% | — | — | — | — |
|---|
| Operating profit QoQ | +11.2% | +6.5% | -8.9% | +7.3% | — |
|---|
| Net profit YoY | +30.9% | — | — | — | — |
|---|
| Net profit QoQ | +211.4% | -59.3% | +43.1% | -27.8% | — |
|---|
| EPS YoY | +30.9% | — | — | — | — |
|---|
| EPS QoQ | +211.4% | -59.3% | +43.1% | -27.8% | — |
|---|
LINCOLN annual results history
Full-year performance for LINCOLN PHARMA LTD, useful for reading each quarter in context.
LINCOLN PHARMA LTD annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹671 cr | ₹623 cr | ₹581 cr | ₹505 cr |
|---|
| Total expenses | ₹588 cr | ₹535 cr | ₹482 cr | ₹424 cr |
|---|
| Gross profit | ₹360 cr | ₹332 cr | ₹302 cr | ₹262 cr |
|---|
| Operating profit (EBIT) | ₹83.18 cr | ₹88.59 cr | ₹89.62 cr | ₹80.68 cr |
|---|
| Operating margin | 12.4% | 14.2% | 15.4% | 16.0% |
|---|
| Interest cost | ₹1.01 cr | ₹1.88 cr | ₹0.95 cr | ₹1.64 cr |
|---|
| Profit before tax | ₹116 cr | ₹109 cr | ₹122 cr | ₹100 cr |
|---|
| Tax expense | ₹27.73 cr | ₹26.84 cr | ₹28.94 cr | ₹27.58 cr |
|---|
| Effective tax rate | 24.0% | 24.6% | 23.7% | 27.4% |
|---|
| Net profit (PAT) | ₹87.89 cr | ₹82.35 cr | ₹93.3 cr | ₹72.9 cr |
|---|
| Net profit margin | 13.1% | 13.2% | 16.1% | 14.4% |
|---|
| Basic EPS | ₹43.88 | ₹41.11 | ₹46.58 | ₹36.40 |
|---|
| Diluted EPS | ₹43.88 | ₹41.11 | ₹46.58 | ₹36.40 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹177 cr against ₹154 cr in Q1 FY26, and ₹187 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -5.3%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹154 cr, or 86.7% of revenue, with operating profit grew +15.8% year on year.
Margins, tax and profitability
Net profit of ₹36.23 cr works out to a net margin of 20.4% compared with 18.0% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, LINCOLN PHARMA LTD reported profit before tax of ₹47.55 cr, a tax charge of ₹11.32 cr (effective rate 23.8%), interest cost of ₹0.26 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹11.63 cr in Q4 FY26 to ₹36.23 cr in Q1 FY27, a change of +211.4%.
Trailing twelve months and annual context
Across the trailing four quarters LINCOLN PHARMA LTD has generated revenue of ₹694 cr and net profit of ₹96.45 cr, a trailing net margin of 13.9%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹671 cr with net profit of ₹87.89 cr and EPS of ₹43.88, versus the prior year where revenue grew +7.7% and profit grew +6.7%.
What to watch in the next LINCOLN quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
LINCOLN PHARMA LTD has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
LINCOLN results coverage
No results report published for LINCOLN yet — our desk covers each quarter within minutes of the filing.
LINCOLN quarterly results FAQs
What were LINCOLN PHARMA LTD (LINCOLN) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), LINCOLN PHARMA LTD reported revenue of ₹177 cr and net profit of ₹36.23 cr, a change of +30.9% year on year on +15.1% revenue growth. EPS stood at ₹18.09.
What is LINCOLN profit margin in Q1 FY27?
LINCOLN PHARMA LTD posted a net profit margin of 20.4% and an operating margin of 13.3% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹694 cr and net profit ₹96.45 cr.
Did LINCOLN results beat the previous quarter?
LINCOLN PHARMA LTD net profit changed +211.4% quarter on quarter, from ₹11.63 cr in Q4 FY26 to ₹36.23 cr in Q1 FY27.
When are LINCOLN PHARMA LTD (LINCOLN) quarterly results?
LINCOLN PHARMA LTD has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see LINCOLN latest quarterly results?
Results coverage for LINCOLN will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the LINCOLN stock page.
What is LINCOLN PHARMA LTD annual revenue and profit?
For FY26, LINCOLN PHARMA LTD reported full-year revenue of ₹671 cr and net profit of ₹87.89 cr, with EPS of ₹43.88.
How many quarterly results has LINCOLN declared recently?
Past results dates for LINCOLN will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
